Bellicum Pharmaceuticals Overview

  • Founded
  • 2004
Founded
  • Status
  • Public
  • Employees
  • 107
Employees
  • Stock Symbol
  • BLCM
Stock Symbol
  • Share Price
  • $4.17
  • (As of Friday Closing)

Bellicum Pharmaceuticals General Information

Description

Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases. The company's expertise is based on the inclusion of powerful molecular switches planned to eliminate, reduce, or activate therapeutic cells to increase efficacy and safety compared with existing cell therapies. Its pipeline portfolio includes adjunct T-cell therapy (Rivo-cel) to treat leukemias, lymphomas, and genetic blood diseases; CAR T cells technology (BPX-601) to treat prostate, pancreatic, bladder, esophagus, and gastric cancers; and BCMA GoCAR-NK the program targeting B-cell maturation antigen.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 2710 Reed Road
  • Suite 160
  • Houston, TX 77030
  • United States
+1 (832) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Bellicum Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.17 $4.31 $2.62 - $22.50 $25.4M 6.1M 513K -$11.07

Bellicum Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 16,348 27,231 49,616 197,522
Revenue 5,133 7,143 1,120 185
EBITDA (49,112) (101,042) (88,778) (85,598)
Net Income (55,486) (112,477) (98,036) (91,779)
Total Assets 60,493 116,250 121,501 135,528
Total Debt 29,053 38,035 35,963 35,108
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bellicum Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bellicum Pharmaceuticals‘s full profile, request access.

Request a free trial

Bellicum Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Bellicum Pharmaceuticals‘s full profile, request access.

Request a free trial

Bellicum Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherap
Drug Discovery
Houston, TX
107 As of 2019
00000
000000000 - 00000

0000000

idunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco l
0000 000000000
Heidelberg, Germany
000 As of 0000
00000
00000000000 00000

0000 000

idunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco l
0000 000000000
Houston, TX
00 As of 0000
00000
0000000000 0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bellicum Pharmaceuticals Competitors (24)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Affimed Therapeutics Formerly VC-backed Heidelberg, Germany 000 00000 00000000000 00000
0000 000000000000 Venture Capital-Backed Houston, TX 00 00000 0000000000 0 00000
000000 Venture Capital-Backed Utrecht, Netherlands 00 00.000 000000000000 00.000
0000000 0000000000 Venture Capital-Backed Philadelphia, PA 00 00000 00000000000 00000
0000 000000000000 Formerly VC-backed Cambridge, MA 000 00000 00000000 00000
You’re viewing 5 of 24 competitors. Get the full list »

Bellicum Pharmaceuticals Executive Team (15)

Name Title Board Seat Contact Info
Richard Fair Chief Executive Officer & Board Member
Aaron Foster Executive & Senior Vice President
Steven Toler Ph.D Vice President, Pharmaceutical Development
Martha French Vice President, Regulatory Affairs
You’re viewing 4 of 15 executive team members. Get the full list »

Bellicum Pharmaceuticals Board Members (11)

Name Representing Role Since
James Brown AVG Ventures Chairman & Board Member 000 0000
James Daly Self Board Member 000 0000
Jon Stonehouse Self Board Member 000 0000
Judith Klimovsky Self Board Member 000 0000
Reid Huber Ph.D Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Bellicum Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bellicum Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Bellicum Pharmaceuticals‘s full profile, request access.

Request a free trial